{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T11:01:43Z","timestamp":1773745303633,"version":"3.50.1"},"reference-count":30,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T00:00:00Z","timestamp":1657238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003921","name":"Australian Government Department of Health","doi-asserted-by":"publisher","award":["2-D3X513"],"award-info":[{"award-number":["2-D3X513"]}],"id":[{"id":"10.13039\/501100003921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003921","name":"Australian Government Department of Health","doi-asserted-by":"publisher","award":["1176131"],"award-info":[{"award-number":["1176131"]}],"id":[{"id":"10.13039\/501100003921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003921","name":"Australian Government Department of Health","doi-asserted-by":"publisher","award":["2008276"],"award-info":[{"award-number":["2008276"]}],"id":[{"id":"10.13039\/501100003921","id-type":"DOI","asserted-by":"publisher"}]},{"name":"New South Wales Ministry of Health","award":["2-D3X513"],"award-info":[{"award-number":["2-D3X513"]}]},{"name":"New South Wales Ministry of Health","award":["1176131"],"award-info":[{"award-number":["1176131"]}]},{"name":"New South Wales Ministry of Health","award":["2008276"],"award-info":[{"award-number":["2008276"]}]},{"name":"Australian National Health and Medical Research Council (NHMRC)","award":["2-D3X513"],"award-info":[{"award-number":["2-D3X513"]}]},{"name":"Australian National Health and Medical Research Council (NHMRC)","award":["1176131"],"award-info":[{"award-number":["1176131"]}]},{"name":"Australian National Health and Medical Research Council (NHMRC)","award":["2008276"],"award-info":[{"award-number":["2008276"]}]},{"name":"National Health and Medical Research Council (NHMRC)","award":["2-D3X513"],"award-info":[{"award-number":["2-D3X513"]}]},{"name":"National Health and Medical Research Council (NHMRC)","award":["1176131"],"award-info":[{"award-number":["1176131"]}]},{"name":"National Health and Medical Research Council (NHMRC)","award":["2008276"],"award-info":[{"award-number":["2008276"]}]},{"name":"UNSW Sydney","award":["2-D3X513"],"award-info":[{"award-number":["2-D3X513"]}]},{"name":"UNSW Sydney","award":["1176131"],"award-info":[{"award-number":["1176131"]}]},{"name":"UNSW Sydney","award":["2008276"],"award-info":[{"award-number":["2008276"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>This study aimed to identify the factors associated with timely (within four weeks) HCV RNA testing and timely (within six months) DAA initiation following HCV notification in the DAA era. We conducted a cohort study of people with an HCV notification in NSW, Australia. Notifications of positive HCV serology were linked to administrative datasets. Weights were applied to account for spontaneous clearance. Logistic regression analyses were performed. Among 5582 people with an HCV notification during 2016\u20132017, 3867 (69%) were tested for HCV RNA, including 2770 (50%) who received timely testing. Among an estimated 3925 people with chronic HCV infection, 2372 (60%) initiated DAA therapy, including 1370 (35%) who received timely treatment. Factors associated with timely HCV RNA testing included age (\u226530 years), female sex, non-Aboriginal ethnicity, country of birth being Australia, and no history of drug dependence. Factors associated with timely treatment were age (\u226530 years), male sex, non-Aboriginal ethnicity, country of birth being Australia, no history of drug dependence, and HCV\/HIV co-infection. In the DAA era, 50% of people with an HCV notification did not receive timely HCV RNA testing. Most people with an HCV infection received therapy; however, DAA initiation was delayed among many.<\/jats:p>","DOI":"10.3390\/v14071496","type":"journal-article","created":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T00:06:21Z","timestamp":1657497981000},"page":"1496","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Timely Hepatitis C RNA Testing and Treatment in the Era of Direct-Acting Antiviral Therapy among People with Hepatitis C in New South Wales, Australia"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8840-8323","authenticated-orcid":false,"given":"Mohammad T.","family":"Yousafzai","sequence":"first","affiliation":[{"name":"The Kirby Institute, UNSW Sydney, Sydney 2052, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Alavi","sequence":"additional","affiliation":[{"name":"The Kirby Institute, UNSW Sydney, Sydney 2052, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather","family":"Valerio","sequence":"additional","affiliation":[{"name":"The Kirby Institute, UNSW Sydney, Sydney 2052, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2212-2028","authenticated-orcid":false,"given":"Behzad","family":"Hajarizadeh","sequence":"additional","affiliation":[{"name":"The Kirby Institute, UNSW Sydney, Sydney 2052, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1833-2017","authenticated-orcid":false,"given":"Jason","family":"Grebely","sequence":"additional","affiliation":[{"name":"The Kirby Institute, UNSW Sydney, Sydney 2052, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory J.","family":"Dore","sequence":"additional","affiliation":[{"name":"The Kirby Institute, UNSW Sydney, Sydney 2052, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,7,8]]},"reference":[{"key":"ref_1","unstructured":"Wold Health Organization (2021). Global Progress Report on HIV, Viral Hepatitis and Sexually Tramitted Infections, 2021. Accountability for the Global Health Sector Strategies 2016\u20132021: Actions for Impact, World Health Organization."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJM200107053450107","article-title":"Hepatitis C virus infection","volume":"345","author":"Lauer","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.jhep.2014.07.012","article-title":"Natural history of hepatitis C","volume":"61","author":"Westbrook","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_4","unstructured":"World Health Organization (2016). Global Health Sector Strategy on Viral Hepatitis 2016\u20132021: Towards Ending Viral Hepatitis, World Health Organization."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e193","DOI":"10.1038\/ctg.2016.50","article-title":"Hepatitis C Treatment and Barriers to Eradication","volume":"7","author":"Konerman","year":"2016","journal-title":"Clin. Transl. Gastroenterol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S2468-1253(18)30270-X","article-title":"Accelerating the elimination of viral hepatitis: A Lancet Gastroenterology & Hepatology Commission","volume":"4","author":"Cooke","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_7","unstructured":"World Health Organization (2016). Global Report on Access to Hepatitis C Treatment. Focus on Overcoming Barriers, World Health Organization."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"a036913","DOI":"10.1101\/cshperspect.a036913","article-title":"Hepatitis C Virus Epidemiology and the Impact of Interferon-Free Hepatitis C Virus Therapy","volume":"10","author":"Lazarus","year":"2020","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.idc.2018.02.006","article-title":"Elimination of Hepatitis C Virus in Australia: Laying the Foundation","volume":"32","author":"Dore","year":"2018","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/jvh.12852","article-title":"Uptake of direct-acting antiviral treatment for chronic hepatitis C in Australia","volume":"25","author":"Hajarizadeh","year":"2018","journal-title":"J. Viral Hepat."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"332","DOI":"10.5694\/mja2.51204","article-title":"Prescribing of direct-acting antiviral therapy by general practitioners for people with hepatitis C in an unrestricted treatment program","volume":"215","author":"Stafford","year":"2021","journal-title":"Med. J. Aust."},{"key":"ref_12","unstructured":"The Kirby Institute (2018). HIV, Viral Hepatitis and Sexually Transmissible Infections in Australia: Annual Surveillance Report 2018, UNSW Sydney."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Larney, S., Hickman, M., Guy, R., Grebely, J., Dore, G.J., Gray, R.T., Day, C.A., Kimber, J., and Degenhardt, L. (2017). Estimating the number of people who inject drugs in Australia. BMC Public Health, 17.","DOI":"10.1186\/s12889-017-4785-7"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jhep.2020.08.038","article-title":"High hepatitis C treatment uptake among people with recent drug dependence in New South Wales, Australia","volume":"74","author":"Valerio","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_15","unstructured":"Australian Institute of Health and Welfare (2022, February 16). Medicare Benefits Schedule (MBS) Data Collection, Available online: https:\/\/www.aihw.gov.au\/about-our-data\/our-data-collections\/medicare-benefits-schedule-mbs#:~:text=The%20Medicare%20Benefits%20Schedule%20(MBS,)%2C%20patients%20and%20service%20providers."},{"key":"ref_16","unstructured":"Australian Institute of Health and Welfare (2022, February 16). Pharmaceutical Benefits Scheme (PBS) Data Collection, Available online: https:\/\/www.aihw.gov.au\/about-our-data\/our-data-collections\/pharmaceutical-benefits-scheme#:~:text=The%20Pharmaceutical%20Benefits%20Scheme%20(PBS,a%20claim%20has%20been%20processed."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1111\/liv.14227","article-title":"The population level care cascade for hepatitis C in British Columbia, Canada as of 2018: Impact of direct acting antivirals","volume":"39","author":"Bartlett","year":"2019","journal-title":"Liver Int."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1093\/cid\/ciab526","article-title":"Opportunities to enhance linkage to hepatitis C care among hospitalised people with recent drug dependence in New South Wales, Australia: A population-based linkage study","volume":"73","author":"Valerio","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.jhep.2017.10.019","article-title":"The contribution of alcohol use disorder to decompensated cirrhosis among people with hepatitis C: An international study","volume":"68","author":"Alavi","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.jhep.2019.04.014","article-title":"Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia","volume":"71","author":"Alavi","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Shahid, I., Alzahrani, A.R., Al-Ghamdi, S.S., Alanazi, I.M., Rehman, S., and Hassan, S. (2021). Hepatitis C Diagnosis: Simplified Solutions, Predictive Barriers, and Future Promises. Diagnostics, 11.","DOI":"10.3390\/diagnostics11071253"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/hep4.1646","article-title":"Innovations in Hepatitis C Screening and Treatment","volume":"5","author":"Patel","year":"2021","journal-title":"Hepatol. Commun."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1080\/14737159.2017.1400385","article-title":"Hepatitis C point-of-care diagnostics: In search of a single visit diagnosis","volume":"17","author":"Grebely","year":"2017","journal-title":"Expert Rev. Mol. Diagn."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.drugpo.2019.07.002","article-title":"An intervention to improve HCV testing, linkage to care, and treatment among people who use drugs in Tehran, Iran: The Enhance study","volume":"72","author":"Alavi","year":"2019","journal-title":"Int. J. Drug Policy"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"S758","DOI":"10.1093\/infdis\/jiaa366","article-title":"Novel Hepatitic C Virus (HCV) Diagnosis and Treatment Delivery Systems: Facilitating HCV Elimination by Thinking Outside the Clinic","volume":"222","author":"Bajis","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1093\/cid\/ciaa571","article-title":"Progress Towards Elimination of Hepatitis C Infection Among People Who Inject Drugs in Australia: The ETHOS Engage Study","volume":"73","author":"Valerio","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"108706","DOI":"10.1016\/j.drugalcdep.2021.108706","article-title":"The intersection of gender and drug use-related stigma: A mixed methods systematic review and synthesis of the literature","volume":"223","author":"Meyers","year":"2021","journal-title":"Drug Alcohol Depend."},{"key":"ref_28","unstructured":"The Kirby Institute (2020). National Update on HIV, Viral Hepatitis and Sexually Transmissible Infections in Australia: 2009\u20132018, UNSW Sydney."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"792","DOI":"10.7326\/M17-0377","article-title":"Hepatitis B Virus Reactivation Associated with Direct-Acting Antiviral Therapy for Chronic Hepatitis C Virus: A Review of Cases Reported to the U.S. Food and Drug Administration Adverse Event Reporting System","volume":"166","author":"Cao","year":"2017","journal-title":"Ann. Intern. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1071\/AH19194","article-title":"Factors affecting hepatitis C treatment intentions among Aboriginal people in Western Australia: A mixed-methods study","volume":"44","author":"Rashidi","year":"2020","journal-title":"Aust. Health Rev."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/14\/7\/1496\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:46:38Z","timestamp":1760139998000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/14\/7\/1496"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,8]]},"references-count":30,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["v14071496"],"URL":"https:\/\/doi.org\/10.3390\/v14071496","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,8]]}}}